Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

HARMONi-3 Not authorised

2023-504989-37-00 Metastatic Squamous Non-small Cell Lung Cancer 5
Phase I, double-blind, randomized, placebo-controlled study investigating the safety, tolerability and concentrations of the study product K… Not authorised

2023-503909-11-00 Ovarian cancer 1
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants… Not authorised

2022-501697-19-00 Small Lymphocytic Lymphoma (SLL) / Untreated Chronic Ly 5
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Not authorised

2024-516253-49-00 advanced/metastatic HER2-positive breast carcinoma 4
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacody… Not authorised

2024-516660-28-00 Locally advanced, recurrent, or metastatic breast, gast 1
mFBG PET-CT scan for the imaging of pheochromocytoma Pending

2024-513622-35-00 Pheochromocytoma – endocrine adrenal tumor 4
A First-In-Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination with Cemiplimab Works in Adult Participan… Pending

2025-523399-22-00 Melanoma 7
Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Su… Pending

2025-524255-32-00 Cutaneous squamous cell carcinoma (ccSCC) 4
Phase II, open label, single arm, multicenter study to assess the activity and safety of ALectinib as NE O adjuvant therapy in patients with… Pending

2024-519106-12-00 Patients with anaplastic lymphoma kinase positive (ALK+ 4
Fluorescence Intraoperative Surgical Margin Analysis in Head and Neck Cancer: Clinical Validation Pending

2025-522027-95-00 oral squamous cell carcinoma 5
Moonlanding: A phase 2 study of pembrolizumab plus belzutifan, with or without lenvatinib, given before the main treatment for localized kid… Pending

2024-519673-18-00 Patients with localized renal cell carcinoma 4
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Trametin… Pending

2025-524267-20-00 Adjuvant treatment of BRAF V600E or V600K mutation-posi 2
A Phase III study evaluating the efficacy of atezoliumab administration in addition to BCG (Bacillus Calmette-Guerin) for 1 year in patient… Pending

2024-517621-54-00 High-risk non-muscle invasive bladder cancer (NMIBC) af 5
METAREM / META-1 - METAREM :Immunotherapy Master Trial for Advanced Cancers / META-1: Immunotherapy without chemotherapy for advanced lung c… Pending

2025-522655-26-00 METAREM:Patients with advanced cancer, as defined as un 4
A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps Pending

2025-522045-21-00 Melanoma 1
Phase 1/2 evaluating the addition of venetoclax to standard 3+7 and midostaurin induction treatment in patients with FLT3-mutated Acute Myel… Pending

2024-517130-17-00 FLT3-mutated Acute Myeloid Leukemia 9
OVACURE-2 Pending

2025-522659-24-00 Ovarian carcinoma 9
F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival Pending

2023-508709-26-00 Hepatocellular carcinoma 4
Indocyanine Green and near infrared fLuorescence in paediatric Oncology surgery Pending

2024-514089-37-00 Patients with pulmonary metastasis from any primary tum 4
A multicentre, prospective, open-label study with [68Ga]Ga-ABY-025 PET-imaging to characterize HER2-expression and explore the therapy-predi… Pending

2024-512721-89-00 Breast Cancer 4
Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending

2024-517133-40-00 newly diagnosed, non-metastatic, SHH-activated, TP53-wt 5
A Phase 2 Study to Evaluate the Efficacy and Safety of Ampligen® Compared to Control Group / No Treatment Following FOLFIRINOX in Subjects w… Pending

2024-518627-29-00 locally advanced pancreatic cancer 4
64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer Pending

2025-520861-29-00 Prostate cancer at risk of developing metastatic lesion 5
A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123… Pending

2024-520258-39-00 Solid Tumors 3